"Castleman Disease" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Large benign, hyperplastic lymph nodes. The more common hyaline vascular subtype is characterized by small hyaline vascular follicles and interfollicular capillary proliferations. Plasma cells are often present and represent another subtype with the plasma cells containing IgM and IMMUNOGLOBULIN A.
| Descriptor ID |
D005871
|
| MeSH Number(s) |
C15.604.515.245 C20.683.515.250
|
| Concept/Terms |
Castleman Disease- Castleman Disease
- Angiofollicular Lymphoid Hyperplasia
- Angiofollicular Lymphoid Hyperplasias
- Hyperplasia, Angiofollicular Lymphoid
- Lymphoid Hyperplasia, Angiofollicular
- Castleman's Disease
- Angiofollicular Lymph Node Hyperplasia
- Hyperplasia, Giant Lymph Node
- Lymph Node Hyperplasia, Giant
- Angiofollicular Lymph Hyperplasia
- Angiofollicular Lymph Hyperplasias
- Hyperplasia, Angiofollicular Lymph
- Lymph Hyperplasia, Angiofollicular
- Castlemans Disease
- Disease, Castlemans
- Giant Lymph Node Hyperplasia
- Castleman's Tumor
- Castleman Tumor
- Castlemans Tumor
- Tumor, Castleman's
|
Below are MeSH descriptors whose meaning is more general than "Castleman Disease".
Below are MeSH descriptors whose meaning is more specific than "Castleman Disease".
This graph shows the total number of publications written about "Castleman Disease" by people in this website by year, and whether "Castleman Disease" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2022 | 1 | 0 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Castleman Disease" by people in Profiles.
-
Muniraju M, Mutsvunguma LZ, Reidel IG, Escalante GM, Cua S, Musonda W, Calero-Landa J, Farelo MA, Rodriguez E, Li Z, Ogembo JG. Kaposi sarcoma-associated herpesvirus complement control protein (KCP) and glycoprotein K8.1 are not required for viral infection in vitro or in vivo. J Virol. 2024 Jun 13; 98(6):e0057624.
-
Barry KK, Plumptre I, Bazewicz CG, Green BP, Treat JR, Hughes M, Morel KD, Wiss K, Liang MG. Paraneoplastic pemphigus associated with Castleman disease: A multicenter case series. Pediatr Dermatol. 2023 Jan; 40(1):90-95.
-
Kurzrock R, Voorhees PM, Casper C, Furman RR, Fayad L, Lonial S, Borghaei H, Jagannath S, Sokol L, Usmani SZ, van de Velde H, Qin X, Puchalski TA, Hall B, Reddy M, Qi M, van Rhee F. A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman disease. Clin Cancer Res. 2013 Jul 01; 19(13):3659-70.
-
Blanchet GV, Allen HF, Mehrotra SP, Richardson MW. The tumor lysis syndrome in a child with multicentric Castleman disease. J Pediatr Hematol Oncol. 2010 Apr; 32(3):247-9.
-
Owens CL, Weir EG, Ali SZ. Cytopathologic findings in "POEMS" syndrome associated with Castleman disease. Diagn Cytopathol. 2007 Aug; 35(8):512-5.
-
Ecklund K, Hartnell GG. Mediastinal Castleman disease: MR and MRA features. J Thorac Imaging. 1994; 9(3):156-9.